Charts

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced dosing of the first patient in the single ascending dose (SAD) Part 1 of its two-part Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and safety, of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Approximately 49 patients with presumed MASH have been randomized into Part 1 with a 1:

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2023 and provided a corporate strategic update.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced receipt of Safety Review Committee (SRC) approval, recommending that the two-part Phase 2a trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), continue without modification following a blinded safety review of the first six months of study conduct.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases of cardiometabolic diseases, today announced the appointment of Marshall Woodworth as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective March 1, 2024, following his tenure as Acting Chief Financial Officer since October 27, 2023.

Gainers Enveric Biosciences (NASDAQ:ENVB) stock rose 162.3% to $2.18 during Thursday's pre-market session. The company's market cap ...

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has received first site Institutional Review Board (IRB) approval for Alexander Prezioso, M.D., Investigator, Clinical Pharmacology of Miami, in Hialeah, FL, to proceed with the Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon recep

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Acting Chief Financial Officer, will participate in one-on-ones with investors and business development meetings with biopharmaceutical executives at the BIO CEO & Investor Conference, taking place February 26-27, 2024 in New York.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are three stocks to watch this week as they experienced significant price movements worth your attention. The post The Top 3 Stocks to Watch This Week appeared first on InvestorPlace. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow traded ...

Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported ...

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock increased by 55.3% to $5.08 during Thursday's regular session. The market value of ...

Stocks are comfortably higher this afternoon, as investors continue to unpack the Fed's rate decision as well as this morning's jobs data.

U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday. The Dow traded up 0.23% to ...

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) shares are trading higher Thursday after the company announced the U.S. Food and Drug ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market ...

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive pre-clinical safety data of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in combination with sitagliptin, a DPP4 inhibitor. Additionally, having satisfied its 45-day commitment with the U.S. Food and Drug Administration (FDA) related to its amended protocol, the company has opened enrollment for Part 2 of its Phase 2a

By David Bautz, PhD NASDAQ:NRBO READ THE FULL NRBO RESEARCH REPORT We are initiating coverage of NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) with a valuation of $25.00. NeuroBo is a biopharmaceutical company focused on the development of therapies for metabolic diseases with two lead programs: DA-1241: This is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist that is being developed as a

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that on January 8, 2024, it received formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company has regained compliance with Nasdaq's minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result,

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following industry and investor conferences in January:

NeuroBo Pharmaceuticals, Inc.(NASDAQ: NRBO) shares are trading lower in Friday's premarket session after ending Thursday's ...

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). The IND application supports a Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) for the treatment of obesity

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced a 1-for-8 reverse stock split of the Company's Common Stock, par value $0.001. Beginning on December 21, 2023, the Company's Common Stock will trade on The Nasdaq Capital Market on a split adjusted basis.

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Investor Forum sponsored by Zacks Small-Cap Research. held December 14th are now available for online viewing. REGISTER NOW AT: https://bit.ly/41oBqxg The company presentations will be available 24/7 for 90 days. Investors, adv

NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held December 14th. This event is sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/3tcvQkSIt is recommended that investors pre-register and run the online system check to expedite participat

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, Marshall H. Woodworth, Acting Chief Financial Officer and Robert Homolka, Senior Vice President of Clinical Operations, will present a company overview, including updates on the company's promising cardiometabolic assets, DA-1241, in development as a treatment for NASH and DA-172

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate strategic update.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of James P. Tursi, M.D., a pharmaceutical industry veteran, to its Board of Directors, effective November 1, 2023. Dr. Tursi will also serve as a member of the Board's Nominating and Corporate Governance Committee.

Gainers Plus Therapeutics (NASDAQ:PSTV) shares rose 20.3% to $1.48 during Tuesday's after-market session. Today's trading volume for ...

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, and Robert Homolka, Senior Vice-President of Clinical Operations, will present a company overview at the H.C. Wainwright 7th Annual NASH Investor Conference on Tuesday, October 24th at 2:30 pm ET.

Gainers Adial Pharmaceuticals (NASDAQ:ADIL) stock moved upwards by 23.2% to $4.2 during Friday's after-market session. The company's ...

Gainers Armata Pharmaceuticals (AMEX:ARMP) stock rose 42.2% to $1.64 during Monday's regular session. Trading volume for this security ...

Gainers Minerva Neurosciences (NASDAQ:NERV) shares rose 51.1% to $9.1 during Wednesday's regular session. As of 13:37 EST, Minerva ...

Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private ...

NeuroBo Pharmaceuticals Inc(NASDAQ: NRBO) says its DA-1726, a novel oxyntomodulin analog functioning as a glucagon-like peptide-1 ...

Monday's session saw 41 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The ...

Gainers Axcella Health Inc. (NASDAQ: AXLA) rose 71.7% to $0.7450 in pre-market trading after the company reported regulatory path ...

Gainers Gorilla Technology Group Inc. (NASDAQ: GRRR) shares rose 162% to $21.30 in pre-market trading after jumping over 35% on ...

Gainers Neptune Wellness Solutions Inc.(NASDAQ: NEPT) shares rose 106.9% to $0.5482 in pre-market trading on heavy ...

Gainers Immuron (NASDAQ:IMRN) stock rose 42.9% to $2.3 during Monday's pre-market session. The market value of their outstanding shares ...

Gainers Expion360 Inc. (NASDAQ: XPON) shares jumped 175% to $2.70 after the company announced it has been selected as the ...

Gainers Immuron (NASDAQ:IMRN) shares increased by 37.9% to $2.22 during Friday's regular session. As of 12:30 EST, this security is ...

OnFriday, 143 stocks hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: The largest company by ...

Gainers Immuron (NASDAQ:IMRN) stock increased by 42.2% to $2.29 during Friday's pre-market session. The company's market cap stands at ...

NeuroBo Pharmaceuticals's (NASDAQ:NRBO) short percent of float has fallen 47.55% since its last report. The company recently ...

Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results ...

Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 48.2% to $6.03 in pre-market trading after jumping over 20% on Thursday. ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips The trading week is almost complete but we've still got the biggest pre-market stock movers to go over for Friday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers VEON Ltd. (NASDAQ: VEON) shares rose 31.1% to $0.6095 in pre-market trading after the company agreed to sell its Russian ...

Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. ...

Gainers Cosmos Holdings Inc. (NASDAQ: COSM) rose 68% to $0.5500 after surging around 87% on Tuesday. Cosmos Holdings recently ...

Gainers Cosmos Holdings (NASDAQ:COSM) shares moved upwards by 32.2% to $0.43 during Wednesday's pre-market session. The market value of ...

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 156.2% to close at $0.2608 on Thursday after dipping 40% on Wednesday. Fast ...

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares climbed 172% to $0.2769 after dipping 40% on Wednesday. Fast Radius received ...

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 59% to $0.1619 in pre-market trading after dipping 40% on Wednesday. Fast ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares climbed 212.8% to close at $12.51 on Wednesday after partner Ipsen ...

Gainers Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) shares jumped 219% to $12.80 after partner Ipsen reported Onivyde met its ...